AKTX
Akari Therapeutics PLC
NASDAQ: AKTX · HEALTHCARE · BIOTECHNOLOGY
$3.06
-4.86% today
Updated 2026-06-05
Market cap
$16.75M
P/E ratio
0.00
P/S ratio
478,368.50x
EPS (TTM)
$0.00
Dividend yield
—
52W range
$3 – $54
Volume
1.0M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.3
Quality
C+3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$26.78
+775.16%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.05x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-2.49M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-17.75M | $-10.01M | $-19.79M | $-17.30M | $-14.46M |
| EPS | — | — | — | — | $0.00 |
| Free cash flow | $-21.50M | $-16.43M | $-12.55M | $-10.57M | $-2.49M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Akari Therapeutics PLC trades at $3.06. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.
Frequently asked questions
What is Akari Therapeutics PLC's stock price?
Akari Therapeutics PLC (AKTX) trades at $3.06, on a P/S of 478,368.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Akari Therapeutics PLC overvalued?
Akari Therapeutics PLC carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Akari Therapeutics PLC (AKTX)?
The 12-month analyst consensus target is $26.78, about 775.2% above the current $3.06. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio478,368.50x
ROE-195.05%
Beta0.65
50D MA$6.60
200D MA$17.28
Shares out0.00B
Float41.33B
Short ratio—
Avg volume1.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—